Clinical trials: A
Follicular Lymphoma
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma.
- Trial name
- NCT02213263
- Testing
- PF-05280586, MabThera®
- Where
- 423 sites in United States, Austria and 28 more
- Volunteers
- 394 people
- Sponsor
- Pfizer
COPD Exacerbation, COPD
The COPD CARE Study: Evaluating the Impact of a Virtual-First COPD Service on Major Cardiac and Respiratory Events
A 12 month interventional study of up to 1,050 people with COPD to determine if the NuvoAir virtual-first clinical service leads to fewer moderate and severe COPD exacerbations and cardiac events, reduces healthcare utilization…
- Conditions
- COPD Exacerbation, COPD, Cardio/Pulm: Heart Failure
- Trial name
- NCT06379529
- Testing
- NuvoAir clinical service
- Volunteers
- 1,050 people
- Sponsor
- NuvoAir Medical PC
Polycythemia Vera
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
The purpose of this study is to evaluate the safety and tolerability of the JAK2 inhibitor XL019 administered orally in adults with Polycythemia Vera.
- Trial name
- NCT00595829
- Testing
- XL019
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Exelixis
Refractory Schizophrenia
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
This is an adaptive, Phase II/III study in 2 parts (i.e. Part 1 (dose ranging) and Part 2 (Hypothesis testing)). NaBen® is granted Breakthrough Therapy Designation by US FDA as treatment for refractory schizophrenia.
- Trial name
- NCT03094429
- Testing
- NaBen®
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Multiple Myeloma
A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation
The purpose of this study is to evaluate the safety of daratumumab when combined with lenalidomide and dexamethasone in Japanese participants with newly diagnosed multiple myeloma who are not candidates for high-dose chemotherapy…
- Trial name
- NCT02918331
- Testing
- Daratumumab (16 mg/kg), Lenalidomide, Dexamethasone
- Where
- 5 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Janssen Pharmaceutical K.K.
Osteoarthritis, Overweight or Obesity
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have…
- Trial name
- ENLIGHTEN-4 (NCT07353931)
- Testing
- Eloralintide
- Where
- 153 sites in United States, Argentina and 12 more
- Volunteers
- 900 people
- Sponsor
- Eli Lilly and Company
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
The purpose of this study is to: evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 evaluate the efficacy, safety, tolerability, PK…
- Trial name
- NCT06845202
- Testing
- ALN-4324
- Where
- 22 sites in United States, Argentina and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Overweight and Obesity
A Phase I Study of GZR18 Injection in Obese/Overweight Subjects
This is a randomized, double-blind, placebo-controlled, dose-escalation phase I clinical study. A sequential design is used in this trial with a single dose escalation climb test, to investigate the safety, tolerability, and…
- Trial name
- NCT06548945
- Testing
- GZR18
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Degenerative Lumbar Spinal Stenosis
A Follow-up Study to Evaluate the Efficacy and Safety of Novomax in Posterior Lumbar Interbody Fusion
This is a long-term follow-up study for more than 3 years to evaluate the efficacy and safety of bioactive glass-ceramic intervertebral spacer (Novomax) in posterior lumbar interbody fusion.
- Trial name
- NCT03532945
- Testing
- Bioactive Glass-Ceramic Spacer, Titanium cage
- Volunteers
- 62 people
- Sponsor
- BioAlpha Inc.
Chronic Hepatitis B
A Study to Evaluate the Mass Balance Absorption and AME of VBR
This Phase 1 Study will determine the mass balance recovery, absorption, metabolism, and excretion of [14C] Vebicorvir in healthy male subjects
- Trial name
- NCT04637139
- Testing
- Vebicorvir (VBR)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Episodic Cluster Headache
A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache
This is a 49-day study to evaluate the effectiveness of Intranasal Civamide (Zucapsaicin) in the treatment of an episodic cluster headache period compared to placebo (medically inactive substance which does not contain any active…
- Trial name
- NCT00033839
- Testing
- Civamide (Zucapsaicin)
- Where
- 26 sites in United States
- Volunteers
- 60 people
- Sponsor
- Winston Laboratories
Multiple Indications Cancer
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
The purpose of this study is to continue to provide dasatinib to patients that are currently participating in another dasatinib trial that is ending and for which there is no other option to provide dasatinib.
- Trial name
- NCT02297139
- Testing
- Dasatinib
- Where
- 6 sites in France, Poland
- Volunteers
- 17 people
- Sponsor
- Bristol-Myers Squibb
Brain and Central Nervous System Tumors
NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: NBI-3001 may be able to locate cancer cells and stop them from growing. This may be an effective treatment for glioblastoma multiforme.
- Trial name
- NCT00014677
- Testing
- interleukin-4 PE38KDEL cytotoxin, conventional surgery
- Where
- 4 sites in United States
- Sponsor
- Neurocrine Biosciences
Colorectal Cancer
A Prospective Cohort Study on Colorectal Cancer Screening in Community Population
This study will validate the real world results of polygene methylation detection in colorectal cancer in a large prospective community cohort.
- Trial name
- NCT05485077
- Where
- China
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Singlera Genomics Inc.
Diabetes Mellitus Type 2
A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes
The purpose of this study is to assess the potential of BMS-986036 for treatment obese adults with type-2 diabetes.
- Trial name
- NCT02097277
- Testing
- BMS-986036
- Where
- 16 sites in United States, Canada
- Volunteers
- 219 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Study Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid Arthritis
This primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic properties of multiple ascending doses of ATN-103 administered subcutaneously (below the skin) to Japanese subjects with active…
- Trial name
- NCT01007175
- Testing
- ATN-103 10 mg q4wks, ATN-103 30 mg q4wks, ATN-103 80 mg q4wks
- Where
- 15 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Ablynx, a Sanofi company
Bipolar Disorder
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC), compared with placebo plus SoC in delaying the worsening of bipolar disorder symptoms.
- Trial name
- NCT07286175
- Testing
- Brenipatide
- Where
- 87 sites in United States, Argentina and 6 more
- Volunteers
- 400 people
- Sponsor
- Eli Lilly and Company
Respiratory Viral Infection
Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza
The goal of this phase III study is to learn if ZX-7101A for oral suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years.
- Trial name
- ZX-7101A-214 (NCT07095257)
- Testing
- ZX-7101A for oral suspension, Oseltamivir phosphate for oral suspension
- Where
- 2 sites in China
- Volunteers
- 169 people
- Sponsor
- Nanjing Zenshine Pharmaceuticals
Acute Myeloid Leukemia (AML)
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
The purpose of this study is to learn more about the safety and efficacy of ivosidenib taken with azacitidine to treat adult patients with acute myeloid leukemia (AML) who are presenting a gene mutation called IDH1 (isocitrate…
- Trial name
- NCT05907057
- Testing
- Ivosidenib 500mg Oral Tablet, Azacitidine
- Where
- 15 sites in Austria, France and 2 more
- Volunteers
- 245 people
- Sponsor
- Servier Affaires Médicales
Advanced Solid Tumor
Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors
This study is a phase I, dose escalation and dose expansion study of QLS1103, to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of QLS1103 in subjects with advanced solid tumors.
- Trial name
- NCT05884801
- Testing
- QLS1103
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.